DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响

doi:10.16352/j.issn.1001-6325.2023.08.1247

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (8): 1247-1253.doi: 10.16352/j.issn.1001-6325.2023.08.1247

DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响

黄洁, 李润博, 郭建新, 韩健^*

陆军军医大学陆军特色医学中心妇产科,重庆 400042

收稿日期:2022-10-24 修回日期:2022-12-31 出版日期:2023-08-05 发布日期:2023-07-26
通讯作者: ^*hj_obgyn@tmmu.edu.cn
基金资助:
陆军军医大学优秀人才库项目(B-3271)

Expression of DDX5 and DDX17 in ovarian cancer tissues and their effects on proliferation and drug resistance of human ovarian cancer cell line SKOV3

HUANG Jie, LI Runbo, GUO Jianxin, HAN Jian^*

Department of Obstetrics and Gynecology, Army Medical Center of PLA, Army Medical University, Chongqing 400042, China

Received:2022-10-24 Revised:2022-12-31 Online:2023-08-05 Published:2023-07-26
Contact: ^*hj_obgyn@tmmu.edu.cn

摘要/Abstract

摘要： 目的分析DDX5和DDX17在卵巢癌中的表达水平及与患者生存期的关系,并研究其对人卵巢癌细胞系SKOV3增殖及耐药的影响。方法选取40例卵巢癌和27例正常卵巢上皮标本,采用RT-qPCR检测DDX5和DDX17的表达;应用TCGA数据库分析卵巢癌中DDX5和DDX17与患者生存预后的关系;用慢病毒介导的DDX5-shRNA和DDX17-shRNA下调SKOV3细胞中DDX5和DDX17的表达,Western blot验证敲降效果,CCK8法检测细胞增殖能力及对紫杉醇和卡铂的药物敏感性。结果与正常卵巢上皮相比,卵巢癌组织中 DDX5的表达升高,而DDX17的表达明显降低(P＜0.05);高表达DDX5的卵巢癌患者具有较短的无进展生存期和总生存期,而高表达DDX17的卵巢癌患者则有更长的无进展生存期和总生存期;DDX5表达下调抑制SKOV3细胞增殖,而DDX17表达下调后促进增殖; DDX5表达下调后SKOV3细胞对紫杉醇和卡铂的药物敏感性明显增加,而DDX17表达下调后SKOV3细胞对紫杉醇和卡铂的药物敏感性变化不明显。结论 DDX5和DDX17能够调节卵巢癌细胞系的增殖与耐药,可能是卵巢癌发生发展中的重要调节因子。

关键词: 卵巢癌, DDX5, DDX17, 增殖, 耐药

Abstract: Objective To analyze the expression of DDX5 and DDX17 in ovarian cancer and their relationship with patient survival, and to study the effects of DDX5 and DDX17 on proliferation and drug resistance of ovarian cancer cell line SKOV3. Methods The expression of DDX5 and DDX17 was detected by RT-qPCR in tissue samples from 40 cases of ovarian carcinoma and 27 controls. TCGA database was used to analyze the relationship between DDX15/DDX17 and survival prognosis of ovarian cancer patients. The expression of DDX5 and DDX17 in SKOV3 was down-regulated by lentivirus-mediated DDX5-shRNA and DDX17-shRNA. Western blot was used to verify the knockdown effect, and CCK8 was used to detect cell proliferation and resistance to paclitaxel and carboplatin. Results Compared with normal ovarian epithelium, the expression of DDX5 in samples from ovarian carcinoma was increased, while that of DDX17 was decreased significantly(P＜0.05); Ovarian cancer patients with high DDX5 expression had shorter progression-free survival and overall survival time, while those with high DDX17 expression had longer progression-free survival and overall survival time. Down-regulated DDX5 expression inhibited the SKOV3 cells proliferation, while down-regulated DDX17 expression promoted SKOV3 cells proliferation. The drug sensitivity of SKOV3 cells to paclitaxel and carboplatin was significantly increased after the down-regulation of DDX5 expression, while the drug sensitivity of SKOV3 cells to paclitaxel and carboplatin was not significantly changed after the down-regulation of DDX17 expression. Conclusions DDX5 and DDX17 regulate proliferation and drug resistance of ovarian cancer cells, and are potential regulatory factors functioning in ovarian cancer.

Key words: ovarian cancer, DDX5, DDX17, proliferation, drug resistance

中图分类号:

黄洁, 李润博, 郭建新, 韩健. DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响[J]. 基础医学与临床, 2023, 43(8): 1247-1253.

HUANG Jie, LI Runbo, GUO Jianxin, HAN Jian. Expression of DDX5 and DDX17 in ovarian cancer tissues and their effects on proliferation and drug resistance of human ovarian cancer cell line SKOV3[J]. Basic & Clinical Medicine, 2023, 43(8): 1247-1253.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.08.1247

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I8/1247

参考文献

[1]Wang Z, Guo E, Yang B, et al. Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer[J]. Gynecol Oncol, 2021, 163:358-363.
[2]Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 1:1-9.
[3]Ali MAM. DEAD-box RNA helicases: The driving forces behind RNA metabolism at the crossroad of viral replication and antiviral innate immunity[J]. Virus Res, 2021, 296:198352. doi: 10.1016/j.virusres.2021.198352.
[4]Nyamao RM, Wu J, Yu L, et al. Roles of DDX5 in the tumorigenesis, proliferation, differentiation, metastasis and pathway regulation of human malignancies[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871:85-98.
[5]Xue Y, Jia X, Li C, et al. DDX17 promotes hepatocellular carcinoma progression via inhibiting Klf4 transcriptional activity[J]. Cell Death Dis, 2019, 10:814-825.
[6]Wu KJ. The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness[J]. Biomed J, 2020, 43:107-114.
[7]姚莎莎,尚文雯,徐睿,等. 沉默PDK1基因抑制卵巢癌细胞系SKOV3的增殖及侵袭[J]. 基础医学与临床, 2019, 39: 1381-1387.
[8]Wills B, Fan Q, Alexander C, et al. Confusion following treatment of ovarian cancer[J]. Am J Med, 2019, 132: e610-e611.
[9]Luo Q, Que T, Luo H, et al. Upregulation of DEAD box helicase 5 and 17 are correlated with the progression and poor prognosis in gliomas[J]. Pathol Res Pract, 2020, 216:152828. doi: 10.1016/j.prp.2020.152828.
[10]郭菲菲,康岚. Ddx5和Ddx17在肿瘤中的表达调控及意义[J]. 中国科技论文在线精品论文, 2018, 11:862-870.
[11]Zhou HZ, Li F, Cheng ST, et al. DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis[J]. Hepatology, 2022, 75:847-865.
[12]Wortham NC, Ahamed E, Nicol SM, et al. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer[J]. Oncogene, 2009, 28:4053-4064.
[13]Giraud G, Terrone S, Bourgeois CF. Functions of DEAD box RNA helicases DDX5 and DDX17 in chromatin organization and transcriptional regulation[J]. BMB Rep, 2018, 51:613-622.
[14]Cui Y, Hunt A, Li Z, et al. Lead DEAD/H box helicase biomarkers with the therapeutic potential identified by integrated bioinformatic approaches in lung cancer[J]. Comput Struct Biotechnol J, 2020, 19:261-278.
[15]Zhang L, Li X. DEAD-box RNA helicases in cell cycle control and clinical therapy[J]. Cells, 2021, 10:1540-1560.
[16]Xu K, Sun S, Yan M, et al. DDX5 and DDX17-multifaceted proteins in the regulation of tumorigenesis and tumor progression[J]. Front Oncol, 2022, 12:943032.doi: 10.3389/fonc.2022.943032.

DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响

Expression of DDX5 and DDX17 in ovarian cancer tissues and their effects on proliferation and drug resistance of human ovarian cancer cell line SKOV3

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张培波, 李义. 沙棘总黄酮抑制膀胱癌细胞系T24增殖[J]. 基础医学与临床, 2023, 43(7): 1122-1126.
[2]	唐一君, 王文龙, 李江丽, 杨欢, 孙静. LncRNA RP11-686D22.10与乳腺癌患者生存期相关并影响乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2023, 43(7): 1023-1029.
[3]	金晓霞, 陆晓云, 刘玉山, 梁李娜. SIRT2在膀胱尿路上皮癌中的表达、临床意义及其对癌细胞增殖、侵袭和迁移的影响[J]. 基础医学与临床, 2023, 43(7): 1090-1096.
[4]	曾燕坤, 洪小颖, 陈清林. 下调BECN1抑制人白血病细胞系THP-1增殖、侵袭和迁移[J]. 基础医学与临床, 2023, 43(7): 1104-1109.
[5]	苏靓誉, 张振西, 杜文静. TPX2的表达对胰腺癌预后的影响[J]. 基础医学与临床, 2023, 43(6): 875-881.
[6]	侯孟杰, 赵娜, 黄富强, 王亚南, 刘芳铭. 载脂蛋白E通过降低高尔基体膜蛋白73表达抑制小鼠肝癌细胞系增殖[J]. 基础医学与临床, 2023, 43(5): 762-770.
[7]	刘月, 曹阳, 顾伟英, 商丽梅, 刘琰. 地西他滨联合三氧化二砷抑制急性髓系白血病细胞系增殖和促进凋亡[J]. 基础医学与临床, 2023, 43(4): 608-614.
[8]	冷海娜, 张艳, 王晓栋, 张学友, 李洪利. miR-767-5p通过调控TBL1XR1蛋白表达抑制人卵巢癌细胞系侵袭[J]. 基础医学与临床, 2023, 43(3): 408-414.
[9]	王芳芳, 曹慧媛, 汪婧, 王宁, 黄国良. 上调miR-200c-5p的表达抑制人结直肠癌细胞系SW480增殖[J]. 基础医学与临床, 2023, 43(2): 241-245.
[10]	杨良权, 于淼, 姜茜, 张明慧, 杨海松. miR-504调控蛋白酶体激活因子抑制人乳腺癌细胞系MCF-7增殖及迁移[J]. 基础医学与临床, 2023, 43(1): 95-101.
[11]	贺晶, 李艳, 王延峰, 鲍慧. FABP4表达上调促进人子宫内膜癌细胞系HEC-1-A增殖和迁移[J]. 基础医学与临床, 2022, 42(9): 1356-1361.
[12]	张晓雷, 刘静, 李朝萍. Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(9): 1350-1354.
[13]	王娟, 张晓燕, 朱爱华, 于宏波, 范新丹, 汤春辉, 姚秀芳. Ku70高表达促进人卵巢癌细胞系的增值并与卵巢癌患者不良预后相关[J]. 基础医学与临床, 2022, 42(9): 1391-1399.
[14]	沈永华, 汪峻峰, 程泽星, 冯娟娟. 秦皮甲素抑制人鼻咽癌细胞系HNE-3增殖[J]. 基础医学与临床, 2022, 42(8): 1237-1242.
[15]	谢思安, 陈奕阳, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 张澍田. PTOV1表达水平对结直肠癌患者预后的影响[J]. 基础医学与临床, 2022, 42(8): 1176-1181.